Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + mFOLFOXIRI vs mFOLFOX-6 in 1L Metastatic Colorectal Cancer
NCT04230187Phase 3Active, not recruiting
- Sponsor
- Yanhong Deng
- Start
- Sep 2020
- Primary completion
- Sep 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of folinic acid + 5-fluorouracil + oxaliplatin + irinotecan in colorectal cancer (CRC), sponsored by Yanhong Deng. Started Sep 2020; status: active, not recruiting.
02
Drugs
folinic acid + 5-fluorouracil + oxaliplatin + irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04230187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230187.